Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

SAB4200772

Sigma-Aldrich

Anti-BRAF (V600E) antibody produced in rabbit

enhanced validation

affinity isolated antibody

Synonym(s):

Anti-Proto-oncogene B-Raf, p94, Anti-Serine/threonine-protein kinase B-raf, Anti-v-Raf murine sarcoma viral oncogene homolog B1

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.44

biological source

rabbit

Quality Level

200

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

~95 kDa

species reactivity

human

enhanced validation

recombinant expression
Learn more about Antibody Enhanced Validation

concentration

~1 mg/mL

technique(s)

immunoblotting: 2-4 μg/mL using extract of human HEK-293T cells over-expressing BRAF mutant (V600E) protein

UniProt accession no.

P15056

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... BRAF(673)

General description

B-Raf proto-oncogene serine/threonine-protein kinase (BRAF), also known as Serine/threonine-protein kinase B-raf, Proto-oncogene B-Raf, p94, v-Raf murine sarcoma viral oncogene homolog B1, is a member of the RAF family. BRAF is one of the key factors in mitogen-activated protein kinase (MAPK) signaling pathway, which is activated by members of the Ras family upon growth factor-induced stimulation. BRAF controls and regulates numerous essential cellular mechanisms including cell proliferation, differentiation, development, survival, apoptosis and secretion.1-2 In contrast to the majority of oncogenic fusion kinases such as ALK, ROS1, NTRK1 and RET that are receptor tyrosine kinases, BRAF encodes a non-receptor serine/threonine kinase, placing its normal protein localization within the cytoplasm rather than associated with the plasma membrane.3
BRAF is mutated at a high frequency in several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, nonsmall cell lung carcinoma, and adenocarcinoma of lung.

Specificity

Anti-BRAF (V600E) recognizes V600E mutated human BRAF protein. The antibody may be used in various immunochemical techniques including Immunoblotting.

Immunogen

Synthetic peptide from the C-terminal region of human BRAF protein, conjugated to KLH

Application

Immunoblotting: a working concentration of 2-4 g/mL is recommended using extract of human HEK-293T cells over-expressing BRAF mutant (V600E) protein.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nourah Mohammad Obaid et al.
International journal of molecular sciences, 18(3) (2017-03-12)
The development of resistance to previously effective treatments has been a challenge for health care providers and a fear for patients undergoing cancer therapy. This is an unfortunately frequent occurrence for patients undergoing targeted therapy for tumours harboring the activating
Roland Houben et al.
Journal of carcinogenesis, 3, 6-6 (2004-03-30)
Genes of the Raf family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Recently, it was shown that activating mutations of BRaf are found with high frequency in human melanomas. The Ras family member
Nicolas Stransky et al.
Nature communications, 5, 4846-4846 (2014-09-11)
Human cancer genomes harbour a variety of alterations leading to the deregulation of key pathways in tumour cells. The genomic characterization of tumours has uncovered numerous genes recurrently mutated, deleted or amplified, but gene fusions have not been characterized as
Alexandra Thiel et al.
Frontiers in oncology, 3, 281-281 (2013-12-04)
Different genetic aberrations of BRAF have been reported in various malignancies. BRAF is member of the RAS/RAF/MEK/ERK pathway and constitutive activity of this pathway can lead to increased cellular growth, invasion, and metastasis. The most common activating BRAF mutation in
Sara C Shalin
Laboratory investigation; a journal of technical methods and pathology, 97(2), 158-165 (2016-11-29)
Translocations resulting in a kinase fusion are well reported in many tumor types and indeed can be defining, particularly in the case of hematopoietic malignancies. The recent reports of multiple protein kinase fusions within melanocytic neoplasms, particularly in those with
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service